scholarly journals Recurrence Rate, Clinical Outcome, and Cellular Proliferation: Indices as Prognostic Indicators after Incomplete Surgical Excision of Cutaneous Grade II Mast Cell Tumors: 28 Dogs (1994-2002)

2006 ◽  
Vol 20 (4) ◽  
pp. 933-940 ◽  
Author(s):  
Bernard Séguin ◽  
M. Faulkner Besancon ◽  
Jennifer L. McCallan ◽  
Loralei L. Dewe ◽  
Matthew C. Tenwolde ◽  
...  
2002 ◽  
Vol 38 (1) ◽  
pp. 71-73 ◽  
Author(s):  
Chick Weisse ◽  
Frances S. Shofer ◽  
Karin Sorenmo

A retrospective study was performed on 31 dogs with completely excised, grade II, cutaneous mast cell tumors in order to determine recurrence rates and sites. Distant tumor recurrence developed in 22% of dogs, and local tumor recurrence developed in 11% of dogs; however, the vast majority of these animals were incompletely staged initially. Complete surgical excision of grade II mast cell tumors was associated with effective local control in 89% of these dogs. Therefore, adjuvant radiation therapy might not be indicated in the majority of dogs with complete surgical excision.


2021 ◽  
Vol 49 (03) ◽  
pp. 228-228
Author(s):  
Daniela Simon Betz

Gill V, Leibman N, Monette S et al. Prognostic Indicators and Clinical Outcome in Dogs with Subcutaneous Mast Cell Tumors. J Am Anim Hosp Assoc 2020; 56 (4): 215–225 Mastzelltumoren (MZT) sind häufige kutane Neoplasien beim Hund, für die verschiedene prognostische Faktoren beschrieben wurden. Zu diesen zählen der histologische Grad nach Patnaik (3 Grade) oder Kiupel (2 Grade) sowie einige Marker zellulärer Differenzierung wie AgNORs (agyrophylic nuclear organizer regions), Ki-67 oder PCNA (proliferating cell nuclear antigen). Weitere prognostisch aussagekräftige Parameter sind der c-Kit-Mutationsstatus, die mikrovaskuläre Dichte (microvascular density, MVD) und der mitotische Index (MI). Ziel der Studie war, den klinischen Verlauf nach operativer Entfernung subkutaner MZT beim Hund auszuwerten und die Wertigkeit der verschiedenen Prognosefaktoren zu validieren.


2001 ◽  
Vol 218 (7) ◽  
pp. 1120-1123 ◽  
Author(s):  
Bernard Seguin ◽  
Nicole F. Leibman ◽  
Victoria S. Bregazzi ◽  
Gregory K. Ogilvie ◽  
Barbara E. Powers ◽  
...  

2017 ◽  
Vol 53 (5) ◽  
pp. 258-264 ◽  
Author(s):  
Erika Lauren Krick ◽  
Matti Kiupel ◽  
Amy C. Durham ◽  
Tuddow Thaiwong ◽  
Dorothy C. Brown ◽  
...  

ABSTRACT Previous studies have evaluated cellular proliferation indices, KIT expression, and c-kit mutations to predict the clinical behavior of canine mast cell tumors (MCTs). The study purpose was to retrospectively compare mitotic index, argyrophilic nucleolar organizer regions (AgNORs)/nucleus, Ki-67 index, KIT labeling pattern, and internal tandem duplication mutations in c-KIT between stage I and stage II grade II MCTs. Medical records and tumor biopsy samples from dogs with Grade II MCTs with cytological or histopathological regional lymph node evaluation were included. Signalment, tumor location and stage, and presence of a recurrent versus de novo tumor were recorded. Mitotic index, AgNORs/nucleus, Ki-67, KIT staining pattern, and internal tandem duplication mutations in exon 11 of c-KIT were evaluated. Sixty-six tumors (51 stage I; 15 stage II) were included. Only AgNORs/nucleus and recurrent tumors were significantly associated with stage (odds ratio 2.8, 95% confidence interval [CI] 1.0–8.0, P = .049; odds ratio 8.8, 95% CI 1.1–69.5; P = .039). Receiver-operator characteristic analysis showed that the sensitivity and specificity of AgNORs/cell ≥ 1.87 were 93.3% and 27.4%, respectively, (area under the curve: 0.65) for predicting stage. Recurrent tumors and higher AgNORs/nucleus are associated with stage II grade II MCTs; however, an AgNOR cutoff value that reliably predicts lymph node metastasis was not determined.


2021 ◽  
pp. 030098582098513
Author(s):  
Mafalda Casanova ◽  
Sandra Branco ◽  
Inês Berenguer Veiga ◽  
André Barros ◽  
Pedro Faísca

Canine cutaneous mast cell tumors (ccMCTs) are currently graded according to Patnaik and Kiupel grading schemes. The qualitative and semiquantitative parameters applied in these schemes may lead to inter- and intraobserver variability. This study investigates the prognostic value of volume-weighted mean nuclear volume ([Formula: see text]), a stereological estimation that provides information about nuclear size and its variability. [Formula: see text] of 55 ccMCTs was estimated using the “point-sampled intercept” method and compared with histological grade and clinical outcome. The clinical history of dogs treated with surgical excision alone was available for 30 ccMCTs. Statistical differences in [Formula: see text] were found between grade II ([Formula: see text]= 115 ± 29 µm3) and grade III ccMCTs ([Formula: see text]= 197 ± 63 µm3), as well as between low-grade ([Formula: see text]= 113 ± 28 µm3) and high-grade ccMCTs ([Formula: see text]= 184 ± 63 µm3). An optimal cutoff value of [Formula: see text] ≥ 150 µm3 and [Formula: see text] ≥ 140 µm3 was determined for grade III and high-grade ccMCTs, respectively. In terms of prognosis, [Formula: see text] was not able to predict the clinical outcome in 42% of the cases; however, cases with [Formula: see text]<125 µm3 had a favorable outcome. These results indicate that, despite having limited prognostic value when used as a solitary parameter, [Formula: see text] is highly reproducible and is associated with histological grade as well as with benign behavior.


2015 ◽  
Vol 51 (4) ◽  
pp. 231-238 ◽  
Author(s):  
Kelly A. Kraus ◽  
Craig A. Clifford ◽  
Garrett J. Davis ◽  
Kristina M. Kiefer ◽  
Kenneth J. Drobatz

This was a multi-institutional retrospective study evaluating the outcome and clinical parameters associated with the postoperative prognosis of 36 cats with splenic mast cell tumors treated with splenectomy. Clinical parameters reviewed included signalment, clinical history, results of staging tests, surgical variables, administration of blood products, presence of metastasis, postoperative complications, administration of chemotherapy postoperatively, chemotherapy protocol, and response to chemotherapy. Overall median survival time was 390 days (range, 2–1737 days). Administration of a blood product (P &lt; .0001), metastasis to a regional lymph node (P = .022), and evidence of either concurrent or historical neoplasia (P = .037) were negatively associated with survival. Response to chemotherapy (P = .0008) was associated with an improved median survival time. Larger-scale prospective studies evaluating different chemotherapy protocols are required to elucidate the discrepancy between lack of survival benefit with administration of chemotherapy and improvement in survival time with positive response to chemotherapy.


2010 ◽  
Vol 13 (1) ◽  
pp. 26-30 ◽  
Author(s):  
Keith W. Montgomery ◽  
Alexandra van der Woerdt ◽  
Susette M. Aquino ◽  
John S. Sapienza ◽  
Eric C. Ledbetter

2007 ◽  
Vol 44 (3) ◽  
pp. 298-308 ◽  
Author(s):  
J. D. Webster ◽  
V. Yuzbasiyan-Gurkan ◽  
R. A. Miller ◽  
J. B. Kaneene ◽  
M. Kiupel

2016 ◽  
Vol 58 (1) ◽  
pp. 44-52 ◽  
Author(s):  
Trevor W. Moore ◽  
R. Timothy Bentley ◽  
Sarah A. Moore ◽  
Michele Provencher ◽  
Emma E. Warry ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document